[1] DANIEL LAVANCHY.The global burden of hepatitis C.[J].Liver Int,2009,29 Suppl 1:74-81. [2] WHO.Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[M]Geneva:World Health Organization,2018. [3] CHEN SL,MORGAN TR.The natural history of hepatitis C virus (HCV) infection[J].Int J Med Sci,2006:47-52. [4] HUANG YW,YANG SS,FU SC,et al.Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes:a nationwide cohort study[J].Hepatology,2014,60(3):807-814. [5] 杨玉勤.3 371例手术前和输血前患者血清感染性指标检测结果的分析[J].国际检验医学杂志,2009,30(5):504. [6] 耿丽梅,赵亮,石静,等.丙型肝炎的最新传播途径与预防研究进展[J].口岸卫生控制,2016,21(1):50-52. [7] 刘泽芬,金华强,马顺高.术前及输血前患者血清感染性标志物的检测及意义[J].医学理论与实践,2014,27(21):2902-2903. [8] DANIEL LAVANCHY.Evolving epidemiology of hepatitis C virus[J].Clinical microbiology and infection,2011,17(2):107-115. [9] KRAUSE G,TREPKA MJ,WHISENHUNT RS,et al.Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials[J].Infect Control Hosp Epidemiol,2003,24(2):122-127. [10] GERMAIN JM,CARBONNE A,THIERS V,et al.Patient-to-patient transmission of hepatitis C virus through t he use of multidose vials during general anesthesia[J].Infect Control Hosp Epidemiol,2005,26(9):789-792. [11] LOGGI E,GALLI S,VITALE G,et al.Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods[J].PLoS One,2017,12(11):e0187755. [12] MUKHERJEE R,BURNS A,RODDEN D,et al.Diagnosis and management of hepatitis C virus infection[J].J Lab Autom,2015,20(5):519-538. [13] 黄成军,程书权.高灵敏度HCV RNA检测在慢性丙型肝炎患者中的诊断及治疗检测应用[J].分子诊断与治疗杂志,2019,11(5):379-382. [14] 何宇婷,陈雪芳,陈培松,等.高灵敏度HCV RNA检测在术前筛查中的应用[J].分子诊断与治疗杂志,2020,12(4):419-422. [15] 赵宁,李智伟.丙型肝炎防治指南2015年更新版解读[J].中国实用内科杂志,2016,36(3):192-194. [16] WHO.Guidelines for the screening,care and treatment of persons with hepatitis C infection[EB/OL].Geneva:World Health Organization,2014.http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1&ua=1. [17] WELZEL TM,YANG M,SAJEEV G,et al.Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections[J].Adv Ther,2019,36(9):2475-2486. [18] 江克清,钟伏弟.丙型肝炎病毒感染及所致相关疾病的机制研究进展[J].山东医药,2018,58(18):110-112. [19] 张丽,张毓,孙国栋.酶免抗-HCV阳性标本中NAT法及胶体金法检测相关性分析[J].临床输血与检验,2019,21(4):390-393. [20] 中华人民共和国国家卫生和计划生育委员会.丙型肝炎诊断标准(节选)[J].国际流行病学传染病学杂志,2018,45(2):73-74. [21] HA J,PARK Y,KIM HS.Signal-to-cutoff ratios of current anti-HCV assays and a suggestion of new algorithm of supplementary testing[J].Clin Chimica Acta,2019,498:11-15. [22] 陈冬.丙肝患者血清抗-HCV和HCV RNA检测效果分析[J].临床输血与检验,2016,18(4):374-376. [23] 冯小飞,丁国伟,俞海亮,等.医疗机构丙型肝炎诊断治疗现况研究[J].中国艾滋病性病,2020,26(3):247-249. |